In a typical adult without significant comorbidities, which of the following hypnotic agents—Zaleplon, Temazepam (Restoril), Zolpidem (Ambien), Ramelteon, Eszopiclone (Lunesta), or Trazodone—is most appropriate for treating insomnia?

Hypnotic Agent Selection for Insomnia in Adults

Among the agents listed, avoid trazodone entirely, and choose between eszopiclone (Lunesta), zolpidem (Ambien), temazepam (Restoril), zaleplon, or ramelteon based on whether the primary complaint is sleep onset versus sleep maintenance insomnia.

Primary Recommendation Framework

The 2017 American Academy of Sleep Medicine (AASM) clinical practice guideline provides clear direction on these medications 1:

DO NOT USE:

• Trazodone: The AASM explicitly recommends against using trazodone for either sleep onset or sleep maintenance insomnia 1. Despite its widespread off-label use in clinical practice, the evidence does not support its efficacy, and it carries risks of somnolence (RR 2.86 vs placebo) 2.

APPROPRIATE OPTIONS (All WEAK recommendations):

For Sleep Onset Insomnia:

• Zaleplon 10 mg: Specifically indicated for sleep onset only 1
• Ramelteon 8 mg: For sleep onset only 1
• Zolpidem 10 mg: Effective for both onset and maintenance 1
• Eszopiclone (Lunesta) 2-3 mg: Effective for both onset and maintenance 1
• Temazepam (Restoril) 15 mg: Effective for both onset and maintenance 1

For Sleep Maintenance Insomnia:

• Zolpidem 10 mg: Dual indication 1
• Eszopiclone (Lunesta) 2-3 mg: Dual indication 1
• Temazepam (Restoril) 15 mg: Dual indication 1

Clinical Decision Algorithm

Step 1: Identify Primary Sleep Complaint

• Sleep onset only (difficulty falling asleep): Consider zaleplon or ramelteon first
• Sleep maintenance only (frequent awakenings, early morning awakening): Avoid zaleplon and ramelteon
• Both onset and maintenance: Choose from zolpidem, eszopiclone, or temazepam

Step 2: Consider Safety Profile

Zaleplon has the most favorable next-day profile due to its ultra-short half-life (~1 hour). Memory impairment and psychomotor effects resolve within 2-4 hours 3. However, it only addresses sleep onset 3.

Ramelteon has the best safety profile overall—no abuse potential, no withdrawal, no rebound insomnia 4. It works via melatonin receptors rather than sedation, making it ideal for patients with substance abuse history or concerns about dependence. Limitation: only effective for sleep onset 1.

Eszopiclone and Zolpidem (non-benzodiazepines) have similar efficacy but notable adverse effects:

• Both increase risk of somnolence (RR 2.00 and 1.85 respectively) 2
• Both increase dizziness risk (RR 3.18 and 2.33) 2
• Eszopiclone causes significant dysgeusia/bad taste (RR 10.54) 2
• Both carry FDA warnings about complex sleep behaviors (sleep-driving, sleep-eating) 3, 5

Temazepam (benzodiazepine) is effective for both onset and maintenance 6 but carries:

• Higher somnolence risk (RR 3.77) 2
• Risk of dependence, withdrawal, and abuse 5
• Should not exceed 7-10 days of use 5
• Contraindicated in respiratory disorders

Step 3: Special Populations

Elderly patients (≥55 years):

• Low-dose doxepin appears optimal (not on your list, but worth noting) 6
• Among your options: ramelteon or zaleplon for onset; eszopiclone for maintenance
• Avoid temazepam due to fall risk and cognitive impairment

Patients with substance abuse history:

• First choice: Ramelteon—no abuse potential 4
• Avoid all benzodiazepines (temazepam) and use non-benzodiazepines cautiously

Patients with respiratory disease:

• Avoid temazepam (respiratory depression risk) 7
• Prefer ramelteon, zaleplon, or eszopiclone

Critical Safety Warnings

All FDA-approved hypnotics except ramelteon carry warnings about complex sleep behaviors including sleep-driving 3, 5. Patients must:

• Take medication immediately before bed
• Ensure ability to get full 7-8 hours sleep
• Avoid alcohol and other CNS depressants
• Stop medication immediately if complex behaviors occur

Temazepam specifically requires additional warnings about 5:

• Risk when combined with opioids (respiratory depression, death)
• Physical dependence and severe withdrawal (seizures, psychosis)
• Pregnancy risks (neonatal sedation/withdrawal)

Practical Recommendation

For typical adult with sleep onset insomnia: Start with ramelteon 8 mg (safest profile) or zaleplon 10 mg (if faster onset needed).

For sleep maintenance or mixed insomnia: Use eszopiclone 2-3 mg or zolpidem 10 mg as first-line among your options. Choose eszopiclone if longer duration needed, but warn about bitter taste.

Avoid temazepam unless non-benzodiazepines have failed, given dependence/withdrawal risks and the AASM's equal recommendation strength for all agents 1.

Never use trazodone for insomnia—this is explicitly recommended against by AASM guidelines despite common clinical practice 1.

Duration Caveat

All these medications are indicated for short-term use only (typically 7-28 days) 5. The guideline evidence base does not support long-term pharmacotherapy as monotherapy. Cognitive behavioral therapy for insomnia (CBT-I) should be considered first-line when available 1, 8.